Key result
Intravenous verapamil (20 mg) reduced myocardial oxygen consumption but did not consistently alter myocardial metabolism or improve myocardial efficiency in patients with hypertrophic cardiomyopathy.
Why the study?
Does intravenous verapamil improve haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy?
Does intravenous verapamil improve haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy?
Intravenous verapamil does not consistently improve haemodynamic function or myocardial metabolism in patients with hypertrophic cardiomyopathy in the short term.
No takes yet. Share an insight, caveat, or question.
Short-term verapamil reduces oxygen consumption without consistent metabolic gains in HCM; leaves open efficacy of chronic therapy or alternatives.
Wilmshurst et al. (1986) studied hypertrophic cardiomyopathy (n=12). intravenous verapamil was evaluated on haemodynamic function and myocardial metabolism. Intravenous verapamil (20 mg) reduced myocardial oxygen consumption but did not consistently alter myocardial metabolism or improve myocardial efficiency in patients with hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: